Spruce Biosciences, Inc. SPRB
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Spruce Biosciences, Inc. (SPRB) is a healthcare company listed in the US with a market value of about $124M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -67%.
About Spruce Biosciences
Spruce Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 144% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5M | $10M | $0 | — | — | — |
| Net income | -$39M | -$53M | -$48M | -$46M | -$42M | -$30M | -$13M |
| Free cash flow | — | -$56M | -$33M | -$42M | -$36M | -$28M | -$13M |
| EPS (diluted) | $-50.83 | $-96.40 | $-93.01 | $-147.01 | $-135.76 | $-369.79 | $-1284.12 |
| Net margin | — | -1079.9% | -475.0% | — | — | — | — |
| ROIC | -66.7% | -140.0% | -50.4% | -49.5% | -28.2% | -14.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Spruce Biosciences pay a dividend?
Not currently.
Is Spruce Biosciences a good stock to buy?
We do not give buy or sell advice. Spruce Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.